Apadamtase Alfa (ADZYNMA apadamtase alfa/cinaxadamtase alfa 500 IU powder and solvent for injection vials)
Apadamtase Alfa risk profile, scheduling, and guidance for claims professionals and care workers . Also known as ADZYNMA apadamtase alfa/cinaxadamtase alfa 500 IU powder and solvent for injection vials.
Apadamtase Alfa (brand names: ADZYNMA apadamtase alfa/cinaxadamtase alfa 500 IU powder and solvent for injection vials) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Specialized enzyme replacement therapy with minimal work capacity impact.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Specialized enzyme replacement therapy with minimal work capacity impact.
Regulatory and Compliance Guidance
When Apadamtase Alfa appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Need to assess this medication across your caseload?
Run a full risk assessment including Apadamtase Alfa interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.